Celera (CRA)

Company

"Celera is a healthcare business that uses knowledge of human variability to provide new tests and services to personalize disease management. Our Products business develops and manufactures molecular diagnostic products that are used by hospitals and other clinical laboratories to detect, characterize, monitor and select treatment for disease. We have a distribution agreement with Abbott, through which we develop and commercialize a wide range of molecular diagnostic products, with Abbott serving as the distribution partner." (company website)

cra(1-1)
CRA 4-month chart
cra(1-1)_1yr
CRA 1-year chart

Buy

3 March 2010. Bought 500 at $6.21.

I see Celera trading in a wide downward channel and having just bounced off the bottom of it after heavy sell-off. It is oversold and I am predicting that it is at the beginning of an up-cycle with room to make profits.

  • Percentage price oscillator (PPO) — below the signal line, but converging back toward it
  • Volume — heavier than normal volume for past two weeks

Based on technical analysis, MarketEdge calls CRA an "avoid" in a "strong downward trend."

Sell

gain Bottom line
3%

9 March 2010. Sold 500 at $6.40.

CRA opened down this morning after a big decline yesterday, triggering my stop-loss order.